Centre D'Oncologie Et De Radiotherapie 37 — Clinical Trial Site

20 Registered trials

11 Currently recruiting

Organisation

Centre D'Oncologie Et De Radiotherapie 37

Location

Chambray-Les-Tours, France

Identifier

ORG-100046686

Address

11 Avenue Du Professeur Alexandre Minkowski, 37170, France

Departments

033014:
MEDICAL ONCOLOGY
Oncologie
Oncologie médicale
Oncologie Radiothérapie
Oncologue
Oncology
Oncology-Radiotherapy
Radiology/Oncology
Radiothérapie
Radiotherapy
Service d’Oncologie médicale
Service de radiothérapie

Clinical trials at this site (20)

Search interface

ALADDIN: evaluation of dAroLutamide Addition to anDrogen Deprivation therapy and radIatioN therapy in newly diagnosed prostate cancer with p… Pending

2024-517285-41-00 Newly diagnosed prostate cancer with pelvic lymph nodes 5
Skipping Hormone Therapy in Low-Risk Early Breast Cancer Pending

2025-523683-20-00 Postmenopausal patients with small (pT1a-b pN0) hormone 4
A clinical study of sacituzumab tirumotecan for cervical cancer (MK-2870-036) Recruiting

2025-521514-26-00 Persistent, Recurrent, or Newly Diagnosed Metastatic Ce 5 2026-01-26
NoLEEta - Phase III non-inferiority trial of chemotherapy de-escalation in hormone receptorpositive, Her2-negative, intermediate-risk early … Recruiting

2025-520979-13-00 Patients with HR+ HER2- early breast cancer at intermed 5 2025-12-18
Elacestrant versus Standard Endocrine Therapy in Women and Men with Node-positive, Estrogen Receptor-positive, HER2-negative, Early Breast C… Recruiting

2024-515445-42-00 Node-positive, Estrogen Receptor-positive, HER2-negativ 5 2025-03-24
A trial to learn how safe durvalumab with chemotherapy is and how well it works in adults with muscle-invasive bladder cancer Recruiting

2024-519246-75-01 Patients With Muscle-Invasive Bladder Cancer 4 2026-06-15
Personalizing the use of pembrolizumab for patients who have a strong response in early triple negative breast cancer Recruiting

2024-515787-31-00 Patient with early triple-negative breast cancer (TNBC) 5 2025-07-18
Corticodependent or corticoresistant brain radionecrosis after radiotherapy for brain metastases: a multicentre randomized, controlled doub… Recruiting

2024-510893-25-00 Brain metastases of cancer > brain radionecrosis 5 2025-04-29
Treatment with darolutamide +/- radiation therapy for patients with a castration resistant cancer and metastases detected by functional imag… Recruiting

2023-509787-15-00 Patients with localised prostate cancer and high-risk f 5 2025-02-17
Decreasing treatment for metastatic HER2-Positive Breast Cancer with undetectable cancer levels in blood tests Recruiting

2023-509811-98-00 Patients with HER2-positive locally advanced inoperable 4 2025-01-07
SALVOVAR trial: A pragmatic randomized phase III trial to assess the utility of adjusting chemotherapy dose & dosing schedule with the SALVa… Recruiting

2023-508260-30-01 Patients with poor prognostic OVARian cancers based on 5 2024-07-30
An international, multicenter, randomised, superiority phase III, open label, 2-arm study to investigate distant metastasis free survival wi… Recruiting

2022-501453-36-00 Breast cancer 5 2024-02-23
PD-(L)1 iNhibitors with concurrent IRadiation at VAried tumour sites in advanced Non-small cell lung cAncer Recruiting

2024-512173-27-00 Advanced (stage IIIB/IIIC/IV) NSCLC patients eligible f 5 2019-03-21
MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer Ended

2023-504816-14-00 Endometrial cancer 5 2024-03-08
PRODIGE 85 (FFCD 1804) – KANALRAD Prospective randomized phase III study evaluating induction chemotherapy (modified DCF 4 cycles) followed… Ended

2023-505972-32-00 locally advanced anal squamous cell carcinoma 5 2024-02-26
Safety and efficacy analysis of an antibody associated with a chemotherapy for patients with a triple negative metastatic breast cancer. Ended

2022-502369-10-00 Triple negative metastatic breast cancer 5 2023-10-02
DISCUS: A Randomised Phase II Study Comparing 3 vs 6 Cycles of Platinum-based Chemotherapy Prior to Maintenance Avelumab in Advanced Urothel… Ended

2024-518244-20-01 Urothelial Carcinoma 4 2022-04-25
Evaluation of two maintenance therapies (OSE2101 alone or in combination with pembrolizumab) versus best supportive care in patient with pla… Ended

2024-516096-32-00 Platinum sensitive recurrent ovarian cancer 4 2021-08-05
Randomized trial evaluating the addition of nivolumab to cisplatin-radiotherapy combination for treatment of cancers of the head and neck Ended

2024-513206-65-00 resected squamous cell carcinoma of head and neck 5 2018-08-10
PRODIGE 76-IMMUNOBILADJ: Capecitabine plus durvalumab or capecitabine alone as adjuvant therapy in patients with resected biliary tract carc… Ended

2023-503807-27-00 Biliary tract carcinoma 4